CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接受新辅助化疗与双重 HER2 阻断治疗的 HER2 阳性乳腺癌中的 TIL（肿瘤浸润淋巴细胞）
英文原题：Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
查看英文原题
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
TIL（肿瘤浸润淋巴细胞）与HER2阳性乳腺癌患者接受新辅助化疗和trastuzumab后的结局相关。然而，在双重HER2靶向治疗背景下，TIL是否可作为预后和/或预测性生物标志物仍不清楚。
本研究评估TRAIN-2试验中389例II–III期HER2阳性乳腺癌患者的TIL与病理应答（pCR）及浸润性无病生存期（IDFS）的关系；患者接受含蒽环类或不含蒽环类化疗联合trastuzumab和pertuzumab的新辅助治疗。尽管TIL与pCR无显著关联，TIL评分≥60%的患者3年IDFS为100%（95% CI 100–100），无论激素受体状态、淋巴结分期及是否达到pCR均如此。
此外，在激素受体阳性患者中，将TIL作为连续变量分析显示，其与pCR呈正相关趋势（TIL每增加10%的校正比值比为1.15，95% CI 0.99–1.34；p=0.070），与IDFS也呈正相关趋势（每增加10%的校正风险比为0.71，95% CI 0.50–1.01；p=0.058）。未发现TIL与蒽环类治疗之间存在交互作用。结果提示，高TIL评分可能有助于识别预后良好的II–III期HER2阳性乳腺癌患者。
展开英文摘要原文
Tumor-infiltrating lymphocytes (TILs) have been associated with outcomes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and trastuzumab.
However, it remains unclear if TILs could be a prognostic and/or predictive biomarker in the context of dual HER2-targeting treatment. In this study, we evaluated the association between TILs and pathological response (pCR) and invasive-disease free survival (IDFS) in 389 patients with stage II-III HER2 positive breast cancer who received neoadjuvant anthracycline-containing or anthracycline-free chemotherapy combined with trastuzumab and pertuzumab in the TRAIN-2 trial.
Although no significant association was seen between TILs and pCR, patients with TIL scores 60% demonstrated an excellent 3-year IDFS of 100% (95% CI 100-100), regardless of hormone receptor status, nodal stage and attainment of pCR.
Additionally, in patients with hormone receptor positive disease, TILs as a continuous variable showed a trend to a positive association with pCR (adjusted Odds Ratio per 10% increase in TILs 1. 15, 95% CI 0. 99-1. 34, p = 0. 070) and IDFS (adjusted Hazard Ratio per 10% increase in TILs 0. 71, 95% CI 0. 50-1. 01, p = 0. 058).
We found no interactions between TILs and anthracycline treatment.
Our results suggest that high TIL scores might be able to identify stage II-III HER2-positive breast cancer patients with a favorable prognosis.
论文信息
- 作者
- Liefaard MC、van der Voort A、van Seijen M、Thijssen B、Sanders J、Vonk S、Mittempergher L、Bhaskaran R
- 第一作者单位
- Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.Netherlands
- 通讯作者单位
- Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. g.sonke@nki.nl.Netherlands
- 期刊
- NPJ breast cancer2024 Apr 18
- 原文标识
- PubMed 38637568 · DOI 10.1038/s41523-024-00636-4
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →